Innate Pharma SA Class A

As of June 30, 2026, Innate Pharma carries a market capitalization of 152.18M, placing it among publicly traded companies globally. Its enterprise value stands at 162.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Innate Pharma's next confirmed earnings release is scheduled for March 25, 2027.

As of June 30, 2026, Innate Pharma has 93.90M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Innate Pharma maintains a current ratio of 0.60, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 2, 2026, Innate Pharma's stock has declined approximately 24.54% over the past 52 weeks. The 50-day moving average sits at 2.20, while the 200-day moving average is 3.46.

As of June 30, 2026, Innate Pharma holds 12.45M in cash and equivalents against 23.08M in total debt, resulting in a net debt position of 15.55M. Total book value stands at -46.28M, with working capital of -15.14M providing operational flexibility.